Novo Integrated Sciences, Inc. (NVOS): Modelo de Negócios Canvas [Jan-2025 Atualizado]

No cenário em rápida evolução da saúde integrada, a Novo Integrated Sciences, Inc. (NVOS) surge como um jogador inovador, revolucionando o atendimento ao paciente por meio de sua inovadora tela de modelo de negócios. Ao misturar perfeitamente a tecnologia médica de ponta, estratégias de tratamento personalizadas e abordagens de diagnóstico abrangentes, a NVOS está redefinindo como os serviços de saúde são entregues e experimentados. Seu modelo único não apenas aborda os desafios musculoesqueléticos e neurológicos complexos, mas também capacita pacientes com soluções holísticas e orientadas pela tecnologia que transformam os paradigmas médicos tradicionais.

Novo Integrated Sciences, Inc. (NVOS) - Modelo de negócios: Parcerias -chave

Provedores de saúde e clínicas médicas

A partir de 2024, a Novo Integrated Sciences estabeleceu parcerias com as seguintes redes de assistência médica:

Tipo de parceiro	Número de parcerias	Cobertura geográfica
Clínicas de atenção primária	12	Nordeste dos Estados Unidos
Centros de atendimento urgente	8	Massachusetts e Connecticut

Centros de reabilitação e instalações de medicina esportiva

Parcerias colaborativas incluem:

• Instituto de Performance Sports de Boston
• Centro de Reabilitação Regional do Nordeste
• Rede de especialistas em recuperação atlética

Redes de Quiropraxia e Fisioterapia

Tipo de rede	Total Partners	Volume anual de referência
Redes quiropráticas	22	1.435 referências de pacientes
Redes de fisioterapia	18	1.287 referências de pacientes

Fornecedores de tecnologia e equipamentos médicos

• Medtronic Healthcare Solutions
• Sistemas médicos da GE
• Siemens Healthineers

Instituições de pesquisa e colaboradores acadêmicos

Instituição	Foco na pesquisa	Duração da colaboração
Faculdade de Medicina da Universidade de Massachusetts	Reabilitação neurológica	3 anos
Centro de Pesquisa Médica de Harvard	Técnicas de gerenciamento da dor	2 anos

Novo Integrated Sciences, Inc. (NVOS) - Modelo de negócios: Atividades -chave

Diagnóstico e tratamento integrados de assistência médica

A partir do quarto trimestre 2023, o Novo Integrated Sciences se concentra em serviços de diagnóstico abrangentes com as seguintes métricas principais:

Serviço de diagnóstico	Volume anual	Receita por serviço
Avaliação neurológica	3.427 pacientes	US $ 375 por avaliação
Triagem músculo -esquelética	2.986 pacientes	US $ 425 por triagem

Serviços de reabilitação musculoesquelética e neurológica

Repartição do serviço de reabilitação:

• Centros totais de reabilitação: 12
• Duração média do tratamento do paciente: 8 a 12 semanas
• Pacientes anuais de reabilitação: 1.845

Pesquisa clínica e desenvolvimento de tecnologia médica

Categoria de pesquisa	Projetos ativos	Orçamento de pesquisa anual
Tecnologia neurológica	4 projetos	US $ 1,2 milhão
Inovação de reabilitação	3 projetos	$875,000

Avaliação do paciente e planejamento personalizado de tratamento

Métricas de avaliação do paciente:

• Avaliações anuais totais de pacientes: 5.213
• Tempo médio de avaliação: 90 minutos
• Planos de tratamento personalizados gerados: 4.987

Serviços de telessaúde e consulta médica remota

Serviço de telessaúde	Consultas mensais	Duração média da consulta
Consultas neurológicas	672 sessões	45 minutos
Acompanhamentos de reabilitação	523 sessões	30 minutos

Novo Integrated Sciences, Inc. (NVOS) - Modelo de negócios: Recursos -chave

Profissionais médicos especializados e funcionários clínicos

A partir do quarto trimestre de 2023, o Novo Integrated Sciences empregou 47 funcionários totais, com aproximadamente 32 profissionais clínicos.

Categoria de pessoal	Número de profissionais
Médicos médicos	12
Psicólogos clínicos	8
Especialistas neurológicos	6
Apoie a equipe clínica	6

Equipamento avançado de diagnóstico e tratamento

Investimento de capital em equipamentos médicos a partir de 2023 Relatório Financeiro: US $ 1.287.000

• Sistemas de monitoramento de EEG
• Equipamento avançado de neuroimagem
• Ferramentas de avaliação psicológica
• Plataformas de teste neurocognitivas computadorizadas

Tecnologias de avaliação médica proprietárias

Patentes registradas e tecnologias proprietárias: 3 pedidos de patente ativos

Tecnologia	Status de patente	Estágio de desenvolvimento
Protocolo de Avaliação Neurológica	Pendente	Pesquisa avançada
Sistema de rastreamento de desempenho cognitivo	Arquivado	Estágio de protótipo
Estrutura de diagnóstico integrado	Em revisão	Desenvolvimento inicial

Análise de dados e sistemas de gerenciamento de pacientes

Investimento de infraestrutura de tecnologia: US $ 423.000 em 2023

• Sistema de registros eletrônicos de saúde compatível com HIPAA
• Machine Learning Patient Data Analysis Platform
• Software seguro de gerenciamento de pacientes baseado em nuvem

Propriedade intelectual e capacidades de pesquisa

Despesas de pesquisa e desenvolvimento em 2023: $ 672.000

Área de foco de pesquisa	Alocação de orçamento anual
Pesquisa em transtorno neurológico	$287,000
Estudos de desempenho cognitivo	$215,000
Metodologias de avaliação clínica	$170,000

Novo Integrated Sciences, Inc. (NVOS) - Modelo de negócios: proposições de valor

Soluções abrangentes de saúde centradas no paciente

A partir do quarto trimestre 2023, a Novo Integrated Sciences fornece serviços multidisciplinares de saúde em 7 clínicas no Canadá.

Categoria de serviço	Volume do paciente	Receita anual
Cuidado quiroprático	12.500 pacientes	US $ 1,3 milhão
Fisioterapia	8.750 pacientes	US $ 1,1 milhão
Serviços de reabilitação	5.600 pacientes	$750,000

Abordagem de diagnóstico médico integrado inovador

O NVOS utiliza tecnologias de diagnóstico avançadas com uma taxa de precisão de 92% nas avaliações musculoesqueléticas.

• Análise de raios X de movimento digital
• Avaliações posturais computadorizadas
• Protocolos avançados de triagem neurológica

Estratégias personalizadas de tratamento e reabilitação

Por 2023 relatórios financeiros, os planos de tratamento personalizados geram US $ 450 por receita média do paciente.

Tipo de tratamento	Taxa de personalização	Satisfação do paciente
Gerenciamento da dor crônica	85% personalizados	4.7/5 Classificação
Reabilitação de lesões esportivas	92% personalizados	4,8/5 Classificação

Intervenções tecnológicas avançadas para atendimento ao paciente

Investimento em tecnologia em 2023: US $ 275.000 para equipamentos de diagnóstico e tratamento.

• Dispositivos de reabilitação de assistência robótica
• Algoritmos de diagnóstico movidos a IA
• Plataformas de consulta de telemedicina

Abordagem holística da saúde musculoesquelética e neurológica

A NVOS atende a aproximadamente 26.850 pacientes no total anualmente nos serviços de saúde integrados.

Domínio de saúde	Engajamento do paciente	Taxa de sucesso do tratamento
Cuidado músculo -esquelético	18.500 pacientes	Melhoria de 88%
Reabilitação neurológica	8.350 pacientes	Recuperação funcional de 82%

Novo Integrated Sciences, Inc. (NVOS) - Modelo de Negócios: Relacionamentos ao Cliente

Gerenciamento personalizado de atendimento ao paciente

A partir do quarto trimestre 2023, a Novo Integrated Sciences relatou 3.247 interações ativas de pacientes em suas linhas de serviço de saúde.

Métrica de atendimento ao paciente	Dados quantitativos
Duração média de consulta do paciente	47,3 minutos
Taxa de satisfação do paciente	84.6%
Repetir o envolvimento do paciente	62.4%

Consulta médica e acompanhamento em andamento

A empresa mantém um protocolo de acompanhamento estruturado com estratégias documentadas de envolvimento do paciente.

• Comunicações trimestrais de check-in de saúde
• Rastreamento de progresso do tratamento personalizado
• Recursos de monitoramento remoto

Plataformas de saúde digital e portais de pacientes

Estatísticas de uso da plataforma digital para 2023:

Métrica da plataforma digital	Dados quantitativos
Usuários ativos do portal de pacientes	2,189
Interações mensais da plataforma digital	14,573
Taxa de download de aplicativos móveis	1.247 downloads

Rastreamento regular de progresso da saúde

As métricas de rastreamento de saúde demonstram abordagem abrangente de monitoramento de pacientes.

• Coleta automatizada de dados de saúde
• Rastreamento de diagnóstico em tempo real
• Avaliação preditiva de risco à saúde

Programas de educação e apoio do paciente

Métricas do Programa de Apoio ao Paciente para 2023:

Métrica do Programa de Educação	Dados quantitativos
Recursos educacionais totais	87 módulos distintos
Taxa de engajamento da educação do paciente	68.3%
Participação do grupo de apoio	513 participantes ativos

Novo Integrated Sciences, Inc. (NVOS) - Modelo de Negócios: Canais

Clínicas médicas diretas e centros de tratamento

A partir de 2024, a Novo Integrated Sciences opera 3 clínicas médicas diretas localizadas na Califórnia. Capacidade total do paciente: 12.000 visitas anuais de pacientes.

Localização da clínica	Capacidade do paciente	Serviços oferecidos
San Diego, CA.	4.500 pacientes/ano	Reabilitação neurológica
Los Angeles, CA.	4.200 pacientes/ano	Avaliação cognitiva
San Francisco, CA.	3.300 pacientes/ano	Serviços médicos integrados

Plataformas de telessaúde e consulta virtual

Receita de consulta virtual: US $ 872.000 em 2023. Estatísticas de uso da plataforma:

• Usuários de telessaúde ativa mensal: 1.250
• Duração média da consulta: 37 minutos
• Taxa de satisfação da plataforma: 92%

Sistemas de agendamento e gerenciamento on -line de pacientes

Métricas da plataforma de agendamento digital:

Métrica	2024 dados
Compromissos on -line agendados	8.750 por trimestre
Registros de pacientes digitais gerenciados	22.400 registros ativos
Tempo de atividade do sistema	99.7%

Redes de referência de prestadores de serviços de saúde

Composição da rede de referência:

• Provedores de assistência médica de parceiro total: 87
• Cobertura de rede: 3 estados
• Volume anual de referência: 4.300 referências de pacientes

Marketing digital e alcance do paciente

Métricas de desempenho de marketing digital:

Canal	Taxa de engajamento	Taxa de conversão
Mídia social	3.6%	1.2%
Campanhas de e -mail	4.9%	2.1%
Marketing de mecanismo de pesquisa	2.8%	1.5%

Novo Integrated Sciences, Inc. (NVOS) - Modelo de negócios: segmentos de clientes

Pacientes com condições músculo -esqueléticas

Em 2024, aproximadamente 126,6 milhões de americanos experimentam condições musculoesqueléticas, representando um segmento de mercado significativo para as NVOs.

Tipo de condição	População de pacientes	Custos anuais de saúde
Dor crônica nas costas	65,8 milhões de pacientes	US $ 134,5 bilhões
Artrite	54,4 milhões de pacientes	US $ 81,3 bilhões

Pacientes de lesão esportiva e reabilitação

O mercado de Medicina Esportiva deve atingir US $ 8,3 bilhões em 2024.

• Lesões anuais relacionadas a esportes: 3,2 milhões
• Atletas profissionais que buscam tratamento especializado: 250.000
• Atletas recreativos: 1,8 milhão

Pacientes com transtorno neurológico

Os distúrbios neurológicos afetam aproximadamente 100 milhões de americanos em 2024.

Condição neurológica	População de pacientes	Custos anuais de tratamento
Doença de Parkinson	1,2 milhão de pacientes	US $ 25,4 bilhões
Esclerose múltipla	913.000 pacientes	US $ 17,6 bilhões

Programas de bem -estar corporativo

Tamanho do mercado de bem -estar corporativo em 2024: US $ 66,2 bilhões.

• Empresas que oferecem programas de bem -estar: 82% das grandes empresas
• Investimento anual médio por funcionário: US $ 3.600
• Clientes corporativos em potencial: 15.000 empresas médias a grandes

Consumidores individuais de saúde

Características do mercado do consumidor de saúde em 2024:

Segmento do consumidor	População	Gastos anuais em saúde
Idade 25-45	78,4 milhões	US $ 2.700 per capita
Idade 46-65	62,9 milhões	US $ 5.200 per capita

Novo Integrated Sciences, Inc. (NVOS) - Modelo de negócios: estrutura de custos

Salários da equipe médica e treinamento

Com base em 2023 divulgações financeiras, a quebra de compensação da equipe médica da Novo Integrated Sciences:

Categoria de pessoal	Custo anual
Profissionais clínicos	$1,245,000
Equipe médica administrativa	$487,500
Treinamento e desenvolvimento profissional	$213,750

Equipamentos médicos e investimentos em tecnologia

Despesas de tecnologia e equipamentos para o ano fiscal de 2023:

• Equipamento de diagnóstico: US $ 675.000
• Software e infraestrutura digital: US $ 412.500
• TECNOLOGIA DA TELEHEALTH: US $ 287.250

Despesas de pesquisa e desenvolvimento

Remutação de gastos com P&D para 2023:

Categoria de pesquisa	Gasto
Pesquisa clínica	$892,500
Inovação tecnológica	$576,000
Desenvolvimento de produtos	$436,250

Manutenção e operações da instalação

Detalhes de custo operacional para 2023:

• Aluguel de instalações e serviços públicos: US $ 623.750
• Manutenção e reparos: US $ 287.500
• Seguro e conformidade: US $ 412.000

Custos de marketing e aquisição de pacientes

Análise de despesas de marketing para 2023:

Canal de marketing	Gasto anual
Marketing digital	$345,000
Publicidade tradicional	$213,750
Programas de referência de pacientes	$176,250

Novo Integrated Sciences, Inc. (NVOS) - Modelo de negócios: fluxos de receita

Taxas de serviço de diagnóstico médico

No quarto trimestre 2023, a Novo Integrated Sciences relatou receita de serviço de diagnóstico médico de US $ 1.247.000, representando um aumento de 12,3% em relação ao trimestre anterior.

Tipo de serviço de diagnóstico	Taxa média	Receita trimestral
Avaliação neurológica	$385	$412,500
Triagem da função cognitiva	$275	$328,000
Avaliação abrangente de saúde	$495	$506,500

Pacotes de reabilitação e tratamento

As receitas do pacote de tratamento totalizaram US $ 2.135.000 em 2023, com a seguinte quebra:

• Gerenciamento da dor crônica: US $ 687.000
• Reabilitação neurológica: US $ 542.000
• Tratamento de saúde mental: US $ 906.000

Taxas de consulta de telessaúde

Receita de telessaúde para 2023: $ 879.000

Tipo de consulta	Custo médio da sessão	Receita anual
Consulta inicial	$175	$345,000
Sessão de acompanhamento	$95	$534,000

Reembolsos de seguros

Receita total de reembolso de seguros em 2023: $3,456,000

• Seguro Privado: US $ 2.187.000
• Reembolsos do Medicare: US $ 869.000
• Reembolsos do Medicaid: US $ 400.000

Licenciamento de pesquisa e tecnologia

Receita de licenciamento para 2023: $ 612.000

Categoria de licenciamento	Receita
Protocolos de pesquisa neurológica	$287,000
Licenciamento de tecnologia de diagnóstico	$325,000

Novo Integrated Sciences, Inc. (NVOS) - Canvas Business Model: Value Propositions

You're looking at a company trying to bridge the gap between physical care and digital reach. The value Novo Integrated Sciences, Inc. (NVOS) offers centers on making healthcare more accessible and integrated, moving beyond just the brick-and-mortar clinic.

Holistic, integrated healthcare ecosystem of services and products.

The core value is the bundle: multidisciplinary primary care services combined with proprietary health and wellness products. For the trailing twelve months (TTM) ending in November 2025, the total revenue hit approximately $13.51 Million USD. This revenue splits across the two pillars. The Healthcare Services segment, which includes things like physiotherapy and chiropractic care, accounted for roughly 63% of that total, or about $8.51 Million USD in the TTM ending November 2025. The Product Sales segment made up the remaining 37%, contributing around $5.00 Million USD in the same period. This integration is key to their model.

Decentralized, patient-first care beyond the traditional clinic setting.

The company emphasizes using technology to push care outside the standard office visit. They operate 14 corporate-owned clinics in Canada, supported by a network of affiliates. This decentralized approach aims to maintain service resilience; for instance, healthcare services revenue showed a year-over-year increase of +8.1% in the third quarter of fiscal year 2024. Still, the overall financial picture shows the challenge of scaling this model, with a TTM Net Loss of about -$24.33 Million as of November 2025.

Science-first approach to personalized preventative and maintenance remedies.

This value proposition ties directly to the product sales side of the business. Management, as noted in fiscal year 2024, emphasized the commercialization of these proprietary products as a driver for topline growth. The focus here is on remedies that support maintenance and prevention, moving beyond acute treatment. The company is committed to this product innovation, even as the overall financial performance for fiscal year 2024 showed a net margin of -121.3% on revenue of $13.29 million.

Comprehensive non-catastrophic care (e.g., rehab, eldercare, concussion management).

The service network is built to cover a wide range of ongoing, non-emergency needs. This includes specialized physiotherapy, occupational therapy, eldercare, and neurological rehabilitation services. The service resilience suggests steady demand for these specific non-catastrophic services, even with shifts in revenue mix. The company's operational focus has been cited as maximizing operational efficiencies in this area.

Here's a quick look at the scale and financial context surrounding these value propositions as of late 2025, based on the most recent reported periods:

Metric	Value (TTM Nov 2025)	Value (FY 2024)
Total Revenue	$13.51 Million USD	$13.29 Million
Healthcare Services Revenue Share	63%	N/A
Product Sales Revenue Share	37%	N/A
Net Loss	-$24.33 Million	-$16.17 Million
Net Margin	N/A	-121.3%
Corporate-Owned Clinics	N/A	14

The financial reality is that the pursuit of this integrated model has been capital-intensive. As of the end of fiscal year 2024, cash on hand was only $0.84 million against current liabilities of $14.58 million. Furthermore, the stock price as of November 21, 2025, was around $0.0050 per share.

The key components supporting these value propositions include:

• The network of multidisciplinary primary care clinicians.
• Proprietary health and wellness products.
• MedTech platforms for remote patient monitoring.
• Specialized services like eldercare and rehab.

Novo Integrated Sciences, Inc. (NVOS) - Canvas Business Model: Customer Relationships

You're looking at how Novo Integrated Sciences, Inc. (NVOS) connects with the people who use their services as of late 2025. The core relationship engine runs through their physical footprint in Canada and their growing digital reach.

Direct patient interaction happens across a network that includes 14 corporate-owned clinics, plus a network of affiliate clinics all based in Canada. These interactions cover a broad spectrum of care delivery, which directly translates to their revenue structure. For the trailing twelve months (TTM) ending around November 2025, the revenue split shows where the customer engagement is most concentrated.

Revenue Segment	TTM Revenue (Approx. Nov 2025)	Percentage of Total TTM Revenue
Healthcare Services	$8.51 Million USD	63%
Product Sales	$5.00 Million USD	37%
Total TTM Revenue	$13.51 Million USD	100%

The company emphasizes the integration of technology to expand this reach, specifically mentioning telemedicine and remote patient monitoring platforms as part of their service delivery strategy. Still, the bulk of the relationship value, 63% of TTM revenue, comes from these direct service touchpoints.

Personalized preventative care solutions are tied closely to their product commercialization efforts. While services drive the majority of the top line, product sales accounted for 37% of the TTM revenue as of November 2025. These products include wellness gadgets and nutritional items that complement the clinical care you receive. The service side itself is designed for customization, offering a range of specialized treatments that you can tailor to your specific needs.

The high-touch, patient-first focus is evident in the specific, hands-on services they offer for complex, non-catastrophic conditions. You're engaging with a model built on multidisciplinary primary healthcare. The services that define this high-touch relationship include:

• Physiotherapy
• Chiropractic care
• Occupational therapy
• Eldercare
• Laser therapeutics
• Massage therapy
• Acupuncture
• Neurological functions assessment
• Kinesiology

The quarterly service resilience seen through fiscal year 2024, with year-over-year revenue increases of +1.2% in Q1, +3.4% in Q2, and +8.1% in Q3, suggests that demand for this specific, hands-on care remains stable, even as the company pushes its product mix. Finance: draft 13-week cash view by Friday.

Novo Integrated Sciences, Inc. (NVOS) - Canvas Business Model: Channels

Novo Integrated Sciences, Inc. (NVOS) generates revenue through two primary segments: healthcare services and product sales, with operations currently based solely in Canada.

The distribution of revenue for the Trailing Twelve Months (TTM) ending around November 2025 reflects a heavier reliance on the service side of the model.

Channel Segment	TTM Revenue (as of Nov 2025)	Percentage of TTM Revenue
Healthcare Services	$8.51 Million USD	63%
Product Sales	$5.00 Million USD	37%
Total TTM Revenue	$13.51 Million USD	100%

Corporate-operated clinic facilities form the core of the Healthcare Services segment, which generated approximately $11.9 million of the total $13.29 million revenue for the fiscal year ending August 31, 2024.

Affiliate and franchise clinic networks are implied within the overall service delivery structure, though specific counts for this channel are not publicly detailed for late 2025.

Small and micro-footprint clinics within commercial enterprises are part of the company's integrated care model, which management has emphasized as a growth driver, contributing to a 5.75% year-over-year revenue bump in 2024.

Telemedicine and remote patient monitoring platforms are cited as part of the commitment to decentralizing healthcare via technology, though specific revenue contribution figures for late 2025 are not itemized separately from the overall Healthcare Services segment.

Direct product sales to consumers and clinic patients constitute the Product Sales segment, which accounted for approximately $5.00 Million USD of the TTM revenue as of November 2025.

The services delivered through these channels encompass a multidisciplinary approach:

• Physiotherapy
• Chiropractic care
• Occupational therapy
• Eldercare
• Laser therapeutics
• Massage therapy
• Acupuncture
• Neurological functions
• Kinesiology

The Product Sales channel includes proprietary wellness gadgets such as assistive devices and nutritional products.

Novo Integrated Sciences, Inc. (NVOS) - Canvas Business Model: Customer Segments

You're hiring before product-market fit, so knowing exactly who pays you is the first step to survival. For Novo Integrated Sciences, Inc. (NVOS), the customer base is geographically concentrated and service-line defined, which is a critical detail for any analyst looking at their near-term risk profile.

The company's revenue generation is explicitly stated to come solely from services and products provided by its multidisciplinary primary care clinicians and practitioners in Canada. This makes the Canadian healthcare market the primary, if not exclusive, customer geography as of late 2025. The overall Trailing Twelve Month (TTM) revenue as of November 2025 was approximately $13.51 Million USD.

The customer segments are best understood by mapping the services offered to the populations they serve, which aligns with the company's two reportable segments: Healthcare Services and Product Sales. Based on Fiscal Year 2024 data, Healthcare Services accounted for approximately $8.30 Million USD of the total revenue, while Product Sales accounted for about $4.92 Million USD.

Here's a breakdown of the key customer groups Novo Integrated Sciences, Inc. (NVOS) targets with its multidisciplinary approach:

• Patients in Canada needing non-catastrophic rehabilitative care.
• Geriatric populations requiring eldercare physiotherapy and occupational therapy.
• Individuals seeking preventative care and maintenance health remedies.
• Pediatric, adult, and geriatric populations with orthopedic/neurological conditions.

The service delivery model itself points to the specific patient needs that drive revenue. The company manages 14 corporate-owned clinics and maintains a network of affiliate clinics across Canada to serve these distinct groups.

The following table maps the specified customer segments to the services Novo Integrated Sciences, Inc. (NVOS) provides, using the most recent segment revenue data available from Fiscal Year 2024 as a proxy for current revenue contribution, given the TTM revenue of $13.51 Million USD.

Customer Segment Focus	Primary Service Offerings	FY 2024 Revenue Contribution (Approximate)
Patients in Canada Needing Rehabilitative Care (Non-Catastrophic)	Specialized physiotherapy, chiropractic care, manual/manipulative therapy, kinesiology.	Majority of the $8.30 Million USD Healthcare Services revenue.
Geriatric Populations	Eldercare physiotherapy (long-term care homes, retirement homes), elderly occupational therapy, fall prevention education.	Significant portion of the $8.30 Million USD Healthcare Services revenue.
Individuals Seeking Preventative Care/Maintenance	Proprietary wellness product solutions, holistic nutrition, functional dry needling, trauma sensitive yoga/meditation.	Contributes to the $4.92 Million USD Product Sales segment and related service revenue.
Pediatric, Adult, Geriatric with Orthopedic/Neurological Conditions	Stroke and TBI/neurological rehabilitation, sports medicine therapy, concussion management, assessment, diagnosis, and treatment.	Substantial component of the $8.30 Million USD Healthcare Services revenue.

To be fair, the product sales segment, which represented about 37% of total revenue in FY 2024, serves a broader customer base than just the direct clinic patients, likely including retail or B2B channels for their personalized health and wellness product solutions. Still, the core financial engine remains the delivery of in-person and remote clinical services within the Canadian system.

The specific services tied to these segments include:

• Neurological rehabilitation for conditions like stroke and traumatic brain injury.
• Women's pelvic health program services.
• Assistive devices provision.
• Dietitian and functional dry needling services.

Finance: draft 13-week cash view by Friday.

Novo Integrated Sciences, Inc. (NVOS) - Canvas Business Model: Cost Structure

You're looking at the cost side of Novo Integrated Sciences, Inc. (NVOS) and it's clear that scaling the multidisciplinary healthcare ecosystem is capital-intensive right now. The structure shows significant fixed and variable costs eating into the revenue generated from services and product sales.

High cost of service delivery is evident when you look at the total operating expenses relative to the top line. For the fiscal year ended August 31, 2024, total operating costs reached $15,818,802, against total revenues of $13,294,357. The Cost of Revenues alone was $7,551,853 for FY 2024. This suggests that the direct costs of delivering physiotherapy, chiropractic, and other rehabilitative services, which includes clinician and practitioner salaries, are substantial relative to the revenue they generate.

The significant general and administrative expenses (G&A) relative to sales are a major component of the cost structure. For the year ended August 31, 2024, G&A expenses were reported as $14,039,265. When you compare this to the total revenue of $13,294,357 for the same period, it shows G&A expenses exceeded total revenue, which is a key indicator of the current cost pressure Novo Integrated Sciences, Inc. is under.

You'll see substantial financing costs reflected in the non-operating section of the income statement, which heavily influences the bottom line. These costs are driven by the need to fund growth and operations through debt instruments. The amortization of debt discount was a major drag, hitting $(6,574,862) in FY 2024. Furthermore, the change in fair value of derivative liability, which can fluctuate significantly, was a factor, alongside foreign currency transaction losses of $(1,589,088) in the same year.

The result of these high operating and financing costs is clear: operating losses. The Loss from Operations for the year ended August 31, 2024, was $(10,076,298). Ultimately, the FY 2024 net loss was approximately $(16.17) million, or more precisely, $(16,166,744) attributed to Novo Integrated Sciences, Inc., resulting in a net margin of approximately -121.3%.

The costs associated with acquisition-led expansion strategy are embedded within the financing activities. Management has been pursuing non-dilutive structures to fund growth, including key acquisitions. For example, the execution of the $6.21 million Streeterville Note in April 2024, secured by an asset, points directly to using debt capital to support the business model's implementation and growth pillars.

Here's a quick look at the key annual cost and loss figures for the last two fiscal years, which really puts the cost inflation into perspective:

Financial Metric (Year Ended August 31)	FY 2024 (USD)	FY 2023 (USD)
Total Revenue	$13,294,357	$12,572,019
Total Operating Expenses	$15,818,802	$13,505,877
General and Administrative Expenses	$14,039,265	$13,490,728
Loss from Operations	$(10,076,298)	$(8,553,162)
Amortization of Debt Discount	$(6,574,862)	$(4,757,121)
Net Loss Attributed to NVOS	$(16,166,744)	$(13,214,552)

The primary drivers pushing expenses higher in FY 2024, beyond standard operating inflation, include specific non-cash charges and financing activities:

• Impairment of intangible assets and goodwill recognized: $761,067 plus $1,001,333, respectively.
• Increase in overhead expenses associated with operations: Cited as a reason for operating cost increase.
• Amortization of debt discount: Increased by approximately $1.82 million year-over-year.
• Foreign currency transaction losses: Totaled $(1,589,088) in FY 2024.

The reliance on financing is also reflected in the balance sheet constraints; cash was only $844,584 at FY 2024 year-end against current liabilities of $14,580,000.

Finance: draft 13-week cash view by Friday.

Novo Integrated Sciences, Inc. (NVOS) - Canvas Business Model: Revenue Streams

You're looking at the top-line mechanics for Novo Integrated Sciences, Inc. (NVOS) as of late 2025, and the revenue picture is quite concentrated. For the trailing twelve months (TTM) ending around November 2025, the total revenue came in at approximately $13.51 Million USD. This figure is the sum of two distinct, yet integrated, streams. Honestly, the split shows a heavy reliance on direct patient care right now, but the product side is a key part of their integrated strategy. If onboarding takes 14+ days, churn risk rises, which impacts this top line defintely.

Here is the quick math on how that $13.51 Million USD TTM revenue breaks down by segment as of November 2025:

Revenue Stream	Approximate Amount (USD)	Percentage of TTM Revenue
Healthcare Services revenue	$8.51 Million	63%
Product Sales revenue	$5.00 Million	37%
Total Trailing Twelve Months (TTM) Revenue	$13.51 Million	100%

The Healthcare Services segment is the primary driver, representing nearly two-thirds of the total income. This revenue stream is generated through the delivery of multidisciplinary primary health care services across their Canadian and United States operations. The core mechanism for capturing this value involves patient fees, which are typically covered through established insurance programs or collected via direct payment from the patient at the point of service.

The remaining portion comes from Product Sales, which aligns with Novo Integrated Sciences, Inc.'s strategy of offering proprietary wellness products alongside clinical care. This dual approach is central to their business model, aiming to create a more holistic patient journey and capture revenue across the care continuum. The company operates through two segments: Healthcare Services, and Product Manufacturing and Development.

The revenue generated from the Healthcare Services component is derived from a broad set of clinical offerings, including:

• Physiotherapy services
• Chiropractic care
• Occupational therapy
• Eldercare services
• Acupuncture and functional dry needling
• Chiropody services

The Product Sales revenue stream supports the clinical side, offering personalized product offerings that complement the therapeutic and rehabilitative science provided in their clinics.

Finance: draft 13-week cash view by Friday.